HeraMED (ASX:HMD) YoY EBITDA Growth: 66.67% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is HeraMED YoY EBITDA Growth?

HeraMED ASX:HMD +2.70% YoY EBITDA Growth is 66.67% as of Dec. 2025. The stock has 2 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. HeraMED's YoY EBITDA Growth for the quarter that ended in Dec. 2025 was 66.67%.

HeraMED's EBITDA per Share for the six months ended in Dec. 2025 was A$-0.00.

HeraMED YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for HeraMED's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HeraMED YoY EBITDA Growth Chart

HeraMED Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial 6.45 34.48 -15.79 54.55 60.00

HeraMED Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -25.00 33.33 70.00 75.00 66.67

HeraMED YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

HeraMED's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(-0.004--0.01)/ | -0.01 |
=60.00 %

HeraMED's YoY EBITDA Growth for the quarter that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (Q: Dec. 2025 )
=(EBITDA per Share (Q: Dec. 2025 )-EBITDA per Share (Q: Dec. 2024 )) / | EBITDA per Share (Q: Dec. 2024 )) |
=(-0.001--0.003)/ | -0.003 |
=66.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 66.67% mean?
HeraMED (ASX:HMD) has a YoY EBITDA Growth of 66.67% as of Dec. 2025. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for HeraMED and its competitors.
Is HeraMED's YoY EBITDA Growth too high?
HeraMED's current YoY EBITDA Growth is 66.67%.
How does HeraMED's YoY EBITDA Growth compare to ABT and SYK?
HeraMED's YoY EBITDA Growth of 66.67% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Medical Devices & Instruments company?
A good YoY EBITDA Growth depends on the Medical Devices & Instruments industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for HeraMED and its competitors. HeraMED's current YoY EBITDA Growth is 66.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HeraMED stock overvalued right now?
Based on GuruFocus' analysis, HeraMED (ASX:HMD) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.04 — trading 90% above its estimated fair value. The current YoY EBITDA Growth is 66.67%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For HeraMED (ASX:HMD), the current YoY EBITDA Growth is 66.67% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

HeraMED Business Description

Other Exchanges 1I4:Germany
Address 117 Camberwell Road, Level 1 - Suite 1, Hawthorn East, Melbourne, VIC, AUS, 3123
HeraMED Ltd is a medical data and technology company providing the digital transformation of maternity care by revolutionizing the prenatal and postpartum experience with its hybrid maternity care platform. It offers a proprietary platform that utilizes hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence. Its offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, and allow healthcare professionals to provide the care and enable early detection and prevention of potential risks.